Preferred Label : Alpelisib;

MeSH note : structure in first source;

CISMeF synonym : NVP-BYL719;

Is substance : O;

UNII : 08W5N2C97Q;

Details


Main resources

You can consult :


https://ansm.sante.fr/tableau-marr/alpelisib
2025
false
false
false
France
French
guidelines for drug use
administration, oral
Drug-Related side effects and adverse reactions
alpelisib
Alpelisib
Alpelisib
continuity of patient care
Hyperglycaemic hyperosmolar nonketotic syndrome
hyperglycemia
ketosis
thiazoles
thiazoles

---
https://ansm.sante.fr/tableau-acces-derogatoire/alpelisib-200-mg-comprimes-pellicules
2024
false
false
false
France
French
Alpelisib
administration, oral
drug information
guidelines for drug use
congenital lipomatous overgrowth, vascular malformations, and epidermal nevi
PIK3CA-related overgrowth syndrome
PIK3CA-Related Overgrowth Spectrum
Phosphatidylinositide 3-Kinase Inhibitor
summary of product characteristics
technical report

---
https://www.has-sante.fr/jcms/p_3233067/fr/piqray
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, oral
alpelisib
Alpelisib/Fulvestrant Regimen
Fulvestrant
antineoplastic agents
antineoplastic agents
antineoplastic combined chemotherapy protocols
class I phosphatidylinositol 3-Kinases
PIK3CA Gene Mutation
breast neoplasms, male
breast neoplasms
postmenopause
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
evaluation of the transparency committee
Alpelisib
Alpelisib
thiazoles
thiazoles
Phosphoinositide-3 Kinase Inhibitors
Phosphoinositide-3 Kinase Inhibitors

---
https://ansm.sante.fr/informations-de-securite/piqray-r-alpelisib-deconditionnement-et-preparation-des-boites-de-50-200-mg-pour-prevenir-les-erreurs-medicamenteuses-liees-a-lindisponibilite-des-comprimes-doses-a-150-mg
2021
false
false
false
France
French
guidelines for drug use
medication errors
alpelisib
phosphatidylinositol 3-Kinases
Alpelisib/Fulvestrant Regimen
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
breast neoplasms
PIK3CA Gene Mutation
breast neoplasms
administration, oral
Alpelisib
Alpelisib
thiazoles
thiazoles
Phosphoinositide-3 Kinase Inhibitors
Phosphoinositide-3 Kinase Inhibitors

---
https://www.ema.europa.eu/en/medicines/human/EPAR/piqray
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
alpelisib
antineoplastic agents
antineoplastic agents
breast neoplasms
postmenopause
antineoplastic combined chemotherapy protocols
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
mutation
PIK3CA Gene Mutation
administration, oral
product surveillance, postmarketing
adult
aged
drug interactions
pregnancy
breast feeding
contraception
class I phosphatidylinositol 3-Kinases
drug evaluation, preclinical
HR-positive, HER2-negative locally advanced breast cancer with PIK3CA mutation
Alpelisib/Fulvestrant Regimen
Alpelisib
Alpelisib
thiazoles
thiazoles
Phosphoinositide-3 Kinase Inhibitors
Phosphoinositide-3 Kinase Inhibitors

---
Nous contacter.
02/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.